NEW YORK, NY / ACCESSWIRE / January 8, 2015 / Healthnostics, Inc. (OTC Pink: HNSS) (PINKSHEETS: HNSS), announced it is expanding the company’s business model to seek out and enter into licensing agreements, acquisitions and investment opportunities focused on bio-medical applications and therapeutic technologies.
The Company has initiated discussions regarding specific licensing opportunities that apply nanoparticle technologies for a variety of over-the-counter therapies. Representatives are working toward completing due diligence and legal and regulatory review of the first applications.
In this process, Healthnostics plans to identify viable medical technology partners requiring development, guidance, financing, marketing and distribution channels to bring these technologies to maturity, in a cooperative incubator strategy.
About Healthnostics, Inc. (www.healthnostics.com)
Healthnostics is a medical and biotechnology analytics company with the mission of helping improve and participate in the delivery of healthcare by providing information resources for the medical and biotechnology fields.
Forward-Looking Statements
This press release may contain certain statements that are not descriptions of historical information, but are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act of 1934. These forward-looking statements refer to matters that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated.
CONTACT:
Healthnostics, Inc.
Investor Relations
[email protected]
SOURCE: Healthnostics, Inc.